Gilder Gagnon Howe & CO LLC Stoke Therapeutics, Inc. Transaction History
Gilder Gagnon Howe & CO LLC
- $7.59 Billion
- Q2 2024
A detailed history of Gilder Gagnon Howe & CO LLC transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Gilder Gagnon Howe & CO LLC holds 88,577 shares of STOK stock, worth $1.08 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
88,577
Previous 89,783
1.34%
Holding current value
$1.08 Million
Previous $1.21 Million
1.32%
% of portfolio
0.02%
Previous 0.02%
Shares
21 transactions
Others Institutions Holding STOK
# of Institutions
117Shares Held
55.6MCall Options Held
14KPut Options Held
8.8K-
Skorpios Trust10.8MShares$133 Million99.89% of portfolio
-
Black Rock Inc. New York, NY5.41MShares$66.2 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.72MShares$57.8 Million4.16% of portfolio
-
Baker Bros. Advisors LP New York, NY4.37MShares$53.5 Million0.78% of portfolio
-
Rtw Investments, LP New York, NY4.22MShares$51.7 Million0.95% of portfolio
About Stoke Therapeutics, Inc.
- Ticker STOK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,419,300
- Market Cap $482M
- Description
- Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...